MorphoSys AG (0NDV.IL)
| Previous close | 67.72 |
| Open | 67.25 |
| Bid | 66.05 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 67.25 - 67.85 |
| 52-week range | 8.40 - 68.35 |
| Volume | |
| Avg. volume | 175,752 |
| Market cap | 2.344B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 26.98 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
- Zacks
Novartis (NVS) to Undertake Job Cuts in Development Department
Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.
- Reuters
UPDATE 3-Novartis begins tender offer for cancer-focused MorphoSys
Novartis said on Thursday it has launched a tender offer to acquire MorphoSys , a German developer of cancer treatments, for an aggregate 2.7 billion euros ($2.9 billion). Reuters reported in February that Swiss drugmaker Novartis would buy MorphoSys, which had an equity market value of around 1.6 billion euros before the offer was announced. The Swiss drugmaker said its cash offer price of 68 euros per MorphoSys share corresponds to a premium of 142% on the volume-weighted average price during the last three months, as of the unaffected closing price on Jan. 25.
